Presentation Description

Pompe Diseases are usually characterized by a deficiency of an enzyme called acid alfa glucosidase (GAA). The enzyme helps by breaking down complex sugars in the body which, when in deficiency causes Pompe disease.


Presentation Transcript

slide 1:

Pompe Disease – Rare but still Matters Pompe Diseases are usually characterized by a deficiency of an enzyme called acid alfa glucosidase GAA. The enzyme helps by breaking down complex sugars in the body which when in deficiency causes Pompe disease. The disease is a rare disorder with a current worldwide prevalence of 1 in 5000 to 10000 people. Global burden aside estimating Pompe disease epidemiology is not easy. Emerging markets such as the UAE and Saudi Arabia are facing several kinds of hindrances in assessing the disease epidemiology correctly due to the limitations in RD and absence of an organized regulatory framework such as the US Orphan Drug Act 1983 and the European Union EU Regulation 141/2000. However available statistics in terms of prevalence in emerging markets show that the number of patients living with Pompe disease was reported to be 52393 in 2017 and is expected to increase to 56572 in 2028 at a CAGR of 0.77. The diagnosis of Pompe disease often poses a diagnostic dilemma due to the rarity of the condition. Moreover the relatively nonspecific nature of the phenotypic features only leads to suspicion of Pompe disease. The diagnostics tool majorly in use to detect Pompe Disease apart

slide 2:

from Clinical evaluation includes- Measurement of GAA activity Level of Glc 4 Mutation analysis. The management of the disease is specific yet incomplete as even though the treatment of Pompe Disease is disease-specific symptomatic and supportive there lies a scope to evolve. Currently the only available treatment regimens for this disease include Enzyme replacement therapy Supportive therapies. Due to the lack of standard treatment options the indication reserves space for research to manage Pompe disease. Although the market has enormous potential for development it is presently defined by a limited number of vendors. Amicus Therapeutics Audentes Therapeutics and Sanofi Genzyme are the major players in the market where Sanofi Genzyme has already produced drugs that have been approved for the treatment for Pompe disease while Amicus Therapeutics and Audentes Therapeutics have their respective drug candidates under clinical trials. Lumizyme alglucosidase alfa is an enzyme replacement therapy produced by recombinant DNA technology which is currently available in the market. It provides an exogenous source of acid α glucosidase GAA an essential lysosomal enzyme that is deficient or absent in patients with Pompe disease leading to intralysosomal glycogen accumulation. AT-GAA is an emerging investigational therapy that consists of ATB200 a unique recombinant human acid alpha-glucosidase rhGAA enzyme with optimized carbohydrate structures particularly mannose-6 phosphate M6P. In Feb 2019 the US Food and Drug Administration FDA granted Amicus a Breakthrough Therapy Designation “BTD” to AT-GAA for the treatment of late-onset Pompe disease. Similarly ACTUS-101 is an investigational gene therapy for Pompe disease that uses a harmless virus called the adeno-associated virus AAV as a vehicle. The gene therapy delivered into the blood specifically targets the liver to promote the production of the GAA enzyme. ACTUS-101 received the fast track designation from USFDA for Pompe disease

slide 3:

As per Delveinsight analysis the therapeutic market of Pompe Disease in the 10 Emerging Markets including UAE and Saudi Arabia from the Middle East region is expected to reach USD 358.20 million by 2028 from USD 116.26 million in 2017 at a Compound Annual Growth Rate CAGR of 10.77 for the study period 2017-2028. DelveInsight’s analysis reveals that the emerging market has propelled the revenue generated from therapeutics ERT for the treatment of PD to a large extent 22 Y/Y basis. “DelveInsight’s estimation suggests that the Middle East is a major contributor to the sales of the drugs for Pompe disease. These regions are also termed as ‘Pharmerging’ markets based on economic parameters such as purchasing power parity PPP indices and absolute spending growths.” As per KOL views and improved diagnostic trends across the globe for Pompe Disease there seems to be largely untapped market waiting to be identified. Although global prevalence estimates quote worldwide PD numbers to be somewhere ranging between 5000-10000 cases recent insights and DelveInsight’s analysis project much larger numbers. These larger numbers are nothing but the potential patient pool representing the highly untapped market which can be capitalized. Improved diagnostic guidelines accompanied by increased use of innovative screening techniques along with the expected relaxed regulatory guidelines and higher governmental insurance coverage will lead to an increase in the market size of PD in the coming years. DUPHAT Source: DelveInsight – www.delveinsight.com

authorStream Live Help